Utility of targeted, amplicon-based deep sequencing to detect resistance to first-line tuberculosis drugs in Botswana

Qiao Wang, Chawangwa Modongo, Christopher Allender, David M. Engelthaler, Robin M. Warren, Nicola M. Zetola, Sanghyuk S. Shin

Research output: Contribution to journalArticlepeer-review

Abstract

Multidrug-resistant tuberculosis (TB) is an alarming threat, and targeted deep sequencing (DS) may be an effective method for rapid identification of drug-resistant profiles, including detection of heteroresistance. We evaluated the sensitivity and specificity of targeted DS versus phenotypic drug susceptibility testing (pDST) among patients starting first-line anti-TB therapy in Botswana. Overall, we found high concordance between DS and pDST. Lower sensitivity of DS, which targets established high-confidence resistance variants, was observed for detecting isoniazid resistance among HIV-infected patients.

Original languageEnglish (US)
Article numbere0098219
JournalAntimicrobial agents and chemotherapy
Volume63
Issue number11
DOIs
StatePublished - 2019
Externally publishedYes

Keywords

  • Diagnostics
  • Drug-resistant tuberculosis
  • HIV infections
  • Heteroresistance
  • Next-generation sequencing
  • Single-molecule overlapping reads

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Utility of targeted, amplicon-based deep sequencing to detect resistance to first-line tuberculosis drugs in Botswana'. Together they form a unique fingerprint.

Cite this